This has been borne out in patients with metastatic clear cell renal cell carcinoma, a malignancy characterized by low TMB, a high frequency of PBRM1‐inactivating mutations (approximately 30%–41% of patients), and improved clinical responses to ICI therapy in the context of PBRM1 mutations [53, 55, 56]. This evidence concerns the gene PBRM1 and clear cell renal carcinoma.